Navigation Links
AMDL Inc. Announces Second Quarter 2008 Results; Company Posts $5.8 Million in Sales With a Revenue Increase of 140%
Date:8/15/2008

injection fluids, tablets and other related products. It currently manufactures over 20 key generic, over-the-counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

Forward-looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(M) (206) 310-5323

(O) (206) 201-3286


'/>"/>
SOURCE AMDL
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
2. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
3. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
4. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
5. Ondine Biopharma Announces Second Quarter 2008 Financial Results
6. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
7. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
10. POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year
11. China Medicine Announces Strong Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... in Australia through ... retail pharmacies nationwide, TAMPA, Fla., ... leader in pharmacy-based patient care services and,healthlinks.net, a subsidiary of ... a definitive technology licensing and business,consulting agreement, paving the way ...
... to receive funding for preclinical and clinical research projects ... ... ROCKLAND, Mass., Oct. 14 The Michael J. Fox Foundation,for ... five,research teams to speed development of effective therapies for the,under-addressed ...
... Logix, a privately held,biopharmaceutical company focused on using ... drugs, is pleased to announce the,appointment of Keith ... Chief,Executive Officer and to its Board of Directors. ... years of leadership experience in the,biotechnology industry., ...
Cached Biology Technology:Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 2Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 4Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 5Surface Logix Appoints Keith Dionne as President and Chief Executive Officer 2
(Date:4/16/2014)... A 20-year assessment of Nicaragua,s legal, artisanal green sea ... overall catch rates of turtles in what may have ... the Wildlife Conservation Society and University of Florida. , ... than 170,000 green turtles were killed between 1991 and ...
(Date:4/16/2014)... From far away, the top of a leaf looks ... exterior is actually made up of a patchwork of ... in how these cells individually take on their own ... Sampathkumar, and colleagues sought to pinpoint the shape-controlling factors ...
(Date:4/16/2014)... as Kennedy,s disease, spinal and bulbar muscular atrophy (SBMA) is ... weakness and atrophy. Researchers have long considered it to be ... in the spinal cord and brainstem that control muscle movement. ... 16, 2014 online issue of Neuron , a team ...
Breaking Biology News(10 mins):Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3For cells, internal stress leads to unique shapes 2Mutant protein in muscle linked to neuromuscular disorder 2
... We all know that iron deficiencies are dangerous, but ... Our body stores excess iron in various tissues, where ... if not treated before irreversible damage has occurred. Researchers ... Germany, and the European Molecular Biology Laboratory (EMBL) now ...
... discovered the stage at which some of the cells of ... cells and why this occurs. The findings of the ... same until the fourth cleavage (division) of the embryo, are ... the cells of the embryo at first undergo equal, symmetrical ...
... of Ebola virus killed tens of thousands of gorillas ... the May issue of The American Naturalist provide new ... transmission between ape social groups. The study provides hope ... of Ebola on wild apes. , Direct encounters ...
Cached Biology News:Putting an old drug to a new use 2Scientists discover stage at which an embryonic cell is fated to become a stem cell 2Ebola outbreaks killing thousands of gorillas and chimpanzees 2
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
... AmpliTaq Gold® DNA Polymerase is a chemically ... the chemical moiety is attached to the ... and the first ramp of thermal cycling ... annealing temperatures), the enzyme is inactive. The ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
Biology Products: